Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely paracetamol 160 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
4 |
Product containing precisely butalbital 50 milligram and paracetamol 650 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and paracetamol 650 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Butalbital 50 mg and paracetamol 650 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely dichloralphenazone 100 milligram and isometheptene 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely dichloralphenazone 100 milligram and isometheptene 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 10 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
3 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 10 mg and paracetamol 660 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Dextropropoxyphene napsylate 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Dextropropoxyphene napsylate 50 mg and paracetamol 325 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 250 mg and salicylamide 600 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely paracetamol 325 milligram and tramadol 37.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and paracetamol 325 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 2.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely oxycodone hydrochloride 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Oxycodone hydrochloride 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Oxycodone hydrochloride 7.5 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Oxycodone hydrochloride 10 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Oxycodone hydrochloride 10 mg and paracetamol 650 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely dextropropoxyphene napsylate 100 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely dextropropoxyphene napsylate 100 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Oxycodone hydrochloride 10 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely oxycodone hydrochloride 2.5 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Oxycodone hydrochloride 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Oxycodone hydrochloride 10 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely oxycodone hydrochloride 2.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely oxycodone hydrochloride 2.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Dihydrocodeine tartrate 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Dihydrocodeine tartrate 10 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Butalbital 50 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and paracetamol 650 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
3 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
3 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
3 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Paracetamol 250 mg and salicylamide 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Paracetamol 250 mg and salicylamide 600 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely paracetamol 325 milligram and tramadol 37.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely paracetamol 325 milligram and tramadol 37.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Oxycodone hydrochloride 7.5 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Oxycodone hydrochloride 7.5 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Paracetamol |
Inferred relationship |
Some |
1 |
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
2 |